GCG and Obesity: Tirzepatide (a GLP-1/GIP) has demonstrated an even greater average of 22.5% weight loss at 72 weeks (9) and aims to reduce multi-morbidity, beyond cardiovascular events, in people with overweight or obesity without diabetes (10).